76
|
Kudo M. Regorafenib as Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma. Liver Cancer 2016; 5:235-244. [PMID: 27781196 PMCID: PMC5075814 DOI: 10.1159/000449335] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
|
77
|
Melero I, Sangro B, Yau T, Hsu C, Kudo M, Crocenzi T, Kim TY, Choo SP, Trojan J, Meyer T, Welling T, Yeo W, Chopra A, Anderson J, De Cruz C, Lang L, Neely J, El-Khoueiry A. Safety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase 1/2 CheckMate-040 study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw371.07] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
78
|
Bruix J, Merle P, Granito A, Huang YH, Bodoky G, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross P, Qin S, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, LeBerre MA, Baumhauer A, Meinhardt G, Han G. Efficacy, safety, and health-related quality of life (HRQoL) of regorafenib in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: Results of the international, double-blind phase 3 RESORCE trial. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw435.19] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
|
79
|
Zhu A, Knox J, Kudo M, Chan S, Finn R, Siegel A, Ma J, Watson P, Cheng AL. Pembrolizumab in patients with previously treated advanced hepatocellular carcinoma: Phase 2 KEYNOTE-224 study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw371.108] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
80
|
Finn R, Chan S, Zhu A, Knox J, Cheng AL, Siegel A, Bautista O, Watson P, Kudo M. Pembrolizumab vs best supportive care for second-line advanced hepatocellular carcinoma: Randomized, phase 3 KEYNOTE-240 study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw371.105] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
81
|
Yuki S, Komatsu Y, Muranaka T, Harada K, Sugiyama J, Tsuji Y, Ando T, Hosokawa A, Hatanaka K, Naruse H, Takahata T, Sato A, Kobayashi Y, Miyagishima T, Okuda H, Kudo M, Nakamura M, Hisai H, Sakamoto N, Sakata Y. Phase II trial of panitumumab monotherapy for patients with KRAS exon2 wild type colorectal cancer after progression on cetuximab. HGCSG1101. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw370.45] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
82
|
Ikeda M, Shimizu S, Sato T, Morimoto M, Kojima Y, Inaba Y, Hagihara A, Kudo M, Nakamori S, Kaneko S, Sugimoto R, Tahara T, Ohmura T, Yasui K, Sato K, Ishii H, Furuse J, Okusaka T. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial. Ann Oncol 2016; 27:2090-2096. [PMID: 27573564 PMCID: PMC5091321 DOI: 10.1093/annonc/mdw323] [Citation(s) in RCA: 108] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2016] [Accepted: 08/04/2016] [Indexed: 12/13/2022] Open
Abstract
In a randomized phase II study of sorafenib plus hepatic arterial infusion chemotherapy with cisplatin in comparison with sorafenib alone in patients with advanced hepatocellular carcinoma, it yielded favorable overall survival when compared with sorafenib alone. This is the first report of its effectiveness in relation to the overall survival in comparison with that of sorafenib alone in patients with advanced hepatocellular carcinoma. Background Sorafenib (Sor) is acknowledged as a standard therapy for advanced hepatocellular carcinoma (HCC). This trial was conducted to evaluate the effect of addition of hepatic arterial infusion chemotherapy with cisplatin (SorCDDP) to Sor for the treatment of advanced HCC. Patients and methods We conducted a multicenter open-labeled randomized phase II trial in chemo-naïve patients with advanced HCC with Child-Pugh scores of 5–7. Eligible patients were randomly assigned 2:1 to receive SorCDDP (sorafenib: 400 mg bid; cisplatin: 65 mg/m2, day 1, every 4–6 weeks) or Sor (400 mg bid). The primary end point was overall survival. Results A total of 108 patients were randomized (Sor, n = 42; SorCDDP, n = 66). The median survival in the Sor and SorCDDP arms were 8.7 and 10.6 months, respectively [stratified hazard ratio (95% confidence interval), 0.60 (0.38–0.96), P = 0.031]. The median time to progression and the response rate were, respectively, 2.8 months and 7.3% in the Sor arm and 3.1 months and 21.7% in the SorCDDP arm. The adverse events were more frequent in the SorCDDP arm than in the Sor arm, but well-tolerated. Conclusion SorCDDP yielded favorable overall survival when compared with Sor in patients with advanced HCC. Clinical Trial registration UMIN-CTR (http://www.umin.ac.jp/ctr/index-j.htm), identification number: UMIN000005703.
Collapse
|
83
|
Kudo M. Risk of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Who Achieved Sustained Virological Response. Liver Cancer 2016; 5:155-61. [PMID: 27493891 PMCID: PMC4960361 DOI: 10.1159/000443563] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
|
84
|
Satoh F, Iwakura Y, Morimoto R, Ono Y, Tezuka Y, Omata K, Nezu M, Igarashi Y, Kudo M, Ito S. Activated Intrarenal Renin Angiotensin Systems Is the Primary Source of Progressing Renal Damage in Primary Aldosteronism. JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION : JASH 2016; 10 Suppl 1:e9. [PMID: 27677148 DOI: 10.1016/j.jash.2016.06.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
|
85
|
|
86
|
Kudo M. Defect Reperfusion Imaging with Sonazoid®: A Breakthrough in Hepatocellular Carcinoma. Liver Cancer 2016; 5:1-7. [PMID: 26989655 PMCID: PMC4789887 DOI: 10.1159/000367760] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
|
87
|
Nakamura M, Yuki S, Sawada K, Oba A, Sato A, Kato T, Meguro T, Ehira N, Tateyama M, Hatanaka K, Eto K, Okuda H, Kobayashi Y, Muto O, Abe M, Kato K, Kudo M, Miyashita K, Sakata Y, Komatsu Y. Updated analysis: Observational cohort study of first-line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802)—Sub-group analysis by KRAS Exon2 status. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.4_suppl.522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
522 Background: A few reports have shown the efficacy of bevacizumab (BV) independent of the KRAS Exon2 mutational status (KRAS). We performed a sub-group analysis by KRAS from the HGCSG0802 observational cohort study that investigated 115 patients (pts) treated with 1st line BV for metastatic colorectal cancer (mCRC). Methods: The objective of HGCSG0802 was to evaluate progression-free survival (PFS), overall survival (OS), response rate (RR), and safety. The key eligibility criteria were with evaluable lesions, older than 20 years, ECOG PS 0-2. In this analysis, pts characteristics, RR and safety were compared using Fisher’s exact test. Univariate and multivariate analysis for PFS and OS were performed using patient characteristics. Survival analyses were performed with Kaplan-Meier method and Cox proportional hazards model. Results: Of 108 pts (the full analysis set), 99 pts were evaluable for KRAS. Sixty-two pts (62.6%) had KRAS wild-type (wt) and 37 pts (37.4%) had mutation (mt). The pts characteristics between those with wt and with mt were generally balanced except for PS 0 (91.9% in wt, 75.7% in mt; p = 0.036) and lung metastasis (33.9% in wt, 62.2% in mt; p = 0.007). RR was 70.0% in wt versus 65.7% in mt. Adverse events related to BV were almost balanced except for bleeding (any grade) (30.6% in wt, 13.5% in mt; p = 0.088). The median PFS and OS was 9.9 and 26.8 months in wt versus 7.9 and 17.5 months in mt (PFS ; HR 1.519, p = 0.064 and OS ; HR 1.944, p = 0.005). In Cox multivariate analysis, KRAS mt showed significantly shorter PFS and OS (PFS ; HR 1.637, p = 0.045 and OS ; HR 2.132, p = 0.005). Conclusions: In this cohort, depending on the KRAS Exon2 mutational status, severe adverse events were no significant difference. The multivariate analysis showed that PFS and OS were significantly longer in the KRAS Exon2 wild-type patients. So, KRAS Exon2 mutational status can be a predictive and prognostic marker in bevacizumab combined 1st line chemotherapy. Clinical trial information: UMIN000018935.
Collapse
|
88
|
Yuki S, Nakatsumi H, Sawada K, Kato T, Meguro T, Nakamura M, Iwanaga I, Ehira N, Sonoda N, Kudo M, Kato K, Sogabe S, Amano T, Ono K, Sakamoto K, Miyamoto N, Kudo K, Sakamoto N, Sakata Y, Komatsu Y. Observational cohort study of first-line bevacizumab with oxaliplatin or irinotecan and fluoropyrimidines in metastatic colorectal cancer: HGCSG0802—Analysis of early tumor shrinkage (ETS). J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.4_suppl.753] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
753 Background: It was reported that early tumor shrinkage (ETS) was associated with better overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) receiving first line chemotherapy. We investigated association of ETS with progression-free survival (PFS) and OS in pts with mCRC treated with first-line bevacizumab (BV)-based chemotherapy (HGCSG0802). Methods: The objective of HGCSG0802 was to evaluate PFS, OS, response rate (RR), safety and so on. The key eligibility criteria were evaluable lesions, older than 20 years old, ECOG PS 0-2. This analysis evaluated the association of ETS at 8 weeks from the start of chemotherapy with pts characteristics, PFS and OS. To identify factors associated with ETS, if there were clinical variables with p < 0.2 in univariate analysis, we planned a multivariate analysis using the logistic regression model. To identify predictive and prognostic factors, a multivariate analysis was performed using Cox proportional hazard model with backward elimination for variables with p < 0.2 in univariate analysis. Results: Of 108 pts (the full analysis set), 99 pts were evaluable for ETS. Sixty-eight pts (68.7%) had ETS ≥20%. The pts characteristics between ETS ≥20% (ETS) and <20% (Non-ETS) were well balanced. In univariate analysis to identify factors associated with ETS, there were no clinical variables with p < 0.2. The median PFS and OS were 7.3/18.3 months in Non-ETS versus 10.0/25.2 months in ETS (HR 0.529; p=0.006 and HR 0.627; p=0.107). In multivariate analysis for PFS and OS, although there was no significant difference between ETS and Non-ETS for OS (HR 0.709; p=0.186), there was significant difference for PFS (HR 0.524; p=0.006). Conclusions: ETS was observed in 68.7% (68/99) and non-ETS in 31.3% (31/99) of patients with metastatic colorectal cancer received bevacizumab combined first line chemotherapy. In univariate analysis, it could not identify any factors associated with ETS. In the results of multivariate analysis, ETS showed an independent predictive impact, but not prognostic impact. Clinical trial information: UMIN000018935.
Collapse
|
89
|
|
90
|
Hosokawa A, Yuki S, Kawamoto Y, Ando T, Muto O, Nakamura M, Kato T, Iwanaga I, Hatanaka K, Tsuji Y, Sato A, Eto K, Furukawa K, Okuda H, Hayashi H, Fujikawa K, Kudo M, Honda T, Sakata Y, Komatsu Y. 162P Updated analysis: Phase II trial of irinotecan plus S-1 (IRIS) with cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type metastatic colorectal cancer (mCRC): HGCSG0902. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv523.23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
91
|
|
92
|
Matsuhashi N, Kudo M, Yoshida N, Murakami K, Kato M, Sanuki T, Oshio A, Joh T, Higuchi K, Haruma K, Nakada K. Factors affecting response to proton pump inhibitor therapy in patients with gastroesophageal reflux disease: a multicenter prospective observational study. J Gastroenterol 2015; 50:1173-83. [PMID: 25851931 DOI: 10.1007/s00535-015-1073-0] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/28/2014] [Accepted: 03/25/2015] [Indexed: 02/04/2023]
Abstract
BACKGROUND Proton pump inhibitor (PPI) therapy, the first-line treatment for gastroesophageal reflux disease (GERD), is not always effective. This study aimed to examine the effect of pretreatment patient characteristics on response to PPI therapy. METHODS Japanese outpatients with symptomatic GERD scheduled to receive endoscopy and PPI therapy were enrolled in this multicenter prospective observational study. The patients' characteristics, including GERD and dyspeptic symptoms, anxiety, depression, and quality of life, were assessed using questionnaires before and 2 and 4 weeks after the start of PPI therapy. Factors affecting therapeutic response were examined by simple and multiple regression analyses using three patient-reported outcome measures as objective variables. RESULTS Data from 182 patients were analyzed. In multiple regression analysis using the residual symptom rate as an objective variable, lower GERD symptom score (p < 0.05), absence of erosive esophagitis (p < 0.05), higher epigastric pain/burning symptom score (p < 0.05), and higher depression subscale score (p < 0.05) accompanied poorer therapeutic response. In analyses using the patient's impression of therapy, lower GERD symptom score (p < 0.05) and absence of erosive esophagitis (p < 0.05) accompanied poorer therapeutic response. In analyses using the relative GERD symptom intensity evaluated using a numeric rating scale, lower GERD symptom score (p < 0.05), higher epigastric pain/burning symptom score (p < 0.1), and lower body mass index (p < 0.05) accompanied poorer therapeutic response. CONCLUSIONS Patients who complained of milder GERD symptoms before treatment were likely to have poorer response to PPI therapy. Association of absence of erosive esophagitis, severer epigastric pain/burning symptoms, lower body mass index, and severer depression with poorer therapeutic response was also suggested.
Collapse
|
93
|
Komatsu Y, Yuki S, Nakatsumi H, Sawada K, Hatanaka K, Kato T, Meguro T, Nakamura M, Iwanaga I, Uebayashi M, Tateyama M, Eto K, Kudo M, Kato K, Okuda H, Sogabe S, Miyagishima T, Miyashita K, Sakamoto N, Sakata Y. 172P Updated analysis: observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin (OX) + BV and oral FU/OX + BV. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv523.33] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
94
|
Yuki S, Komatsu Y, Nakatsumi H, Muranaka T, Kobayashi Y, Miyagishima T, Ehira N, Iwanaga I, Okuda H, Tateyama M, Tsuji Y, Hatanaka K, Nakamura M, Kudo M, Fukushima H, Hisai H, Abe R, Sakamoto N, Oba K, Sakata Y. 157P Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS Exon2 wild-type mCRC: Japanese Skin Toxicity Evaluation Protocol with Panitumumab: J-STEPP/HGCSG1001: updated analysis of anti-tumor efficacy. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv523.18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
95
|
Takahashi Y, Kudo M, Arita M. (Invited) Visualization of Conductive Filament of ReRAM during Resistive Switching by in-situ TEM. ACTA ACUST UNITED AC 2015. [DOI: 10.1149/06910.0299ecst] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
96
|
Sato M, Morimoto R, Seiji K, Iwakura Y, Ono Y, Kudo M, Satoh F, Ito S, Ishibashi T, Takase K. Cost-Effectiveness Analysis of the Diagnosis and Treatment of Primary Aldosteronism in Japan. Horm Metab Res 2015; 47:826-32. [PMID: 26305168 DOI: 10.1055/s-0035-1559645] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Approximately 10% of cases of hypertension in Japan are caused by primary aldosteronism (PA), amounting to about 4 million patients in total. Primary aldosteronism due to unilateral aldosterone hypersecretion is potentially curable by adrenalectomy. The clinical benefits of identifying and treating PA have been reported internationally, but its cost-effectiveness is unclear. We examined whether diagnosing and treating hidden PA in hypertensive population was cost-effective compared with suboptimal treatment. Our hypothetical patient was a 50-year-old man diagnosed with stage I-III hypertension. We established a Markov decision model based on plausible clinical pathways and prognoses of PA. We applied cost-effectiveness analysis comparing a comprehensive diagnostic strategy for PA (measurement of plasma aldosterone/renin ratio, 2 loading tests, imaging, and selective adrenal venous sampling) with a suboptimal strategy to manage hypertension by medication unless the typical signs of PA or other complication were manifest. Outcome measures were expected costs, expected effectiveness, and incremental cost-effectiveness ratio. The robustness of the findings was established by one-way and scenario sensitivity analyses. The comprehensive PA diagnostic strategy increased the expected costs by 64 004 JPY and expected life-years by 0.013 compared with standard treatment. The incremental cost-effectiveness ratio for the diagnosis of PA was 4 923 385 JPY per year. Our findings were sensitive to the outcomes of screening and treatment, and the costs of continuous or periodic medication for hypertension and the treatment of stroke and its complications.
Collapse
|
97
|
Kang YK, Yau T, Park JW, Lim HY, Lee TY, Obi S, Chan SL, Qin S, Kim RD, Casey M, Chen C, Bhattacharyya H, Williams JA, Valota O, Chakrabarti D, Kudo M. Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. Ann Oncol 2015; 26:2457-63. [PMID: 26386123 DOI: 10.1093/annonc/mdv388] [Citation(s) in RCA: 70] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2015] [Accepted: 09/10/2015] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND The efficacy and safety of axitinib, a potent and selective vascular endothelial growth factor receptors 1-3 inhibitor, combined with best supportive care (BSC) was evaluated in a global, randomized, placebo-controlled phase II trial in patients with locally advanced or metastatic hepatocellular carcinoma (HCC). PATIENTS AND METHODS Patients with HCC and Child-Pugh Class A who progressed on or were intolerant to one prior antiangiogenic therapy were stratified by tumour invasion (presence/absence of extrahepatic spread and/or vascular invasion) and region (Asian/non-Asian) and randomized (2:1) to axitinib/BSC (starting dose 5 mg twice-daily) or placebo/BSC. The primary end point was overall survival (OS). RESULTS The estimated hazard ratio for OS was 0.907 [95% confidence interval (CI) 0.646-1.274; one-sided stratified P = 0.287] for axitinib/BSC (n = 134) versus placebo/BSC (n = 68), with the median (95% CI) of 12.7 (10.2-14.9) versus 9.7 (5.9-11.8) months, respectively. Results of prespecified subgroup analyses in Asian versus non-Asian patients or presence versus absence of tumour invasion were consistent with the overall population. Improvements favouring axitinib/BSC (P < 0.01) were observed in secondary efficacy end point analyses [progression-free survival (PFS), time to tumour progression (TTP), and clinical benefit rate (CBR)], and were retained among Asian patients in the prespecified subgroup analyses. Overall response rate did not differ significantly between treatments and patient-reported outcomes favoured placebo/BSC. Most common all-causality adverse events with axitinib/BSC were diarrhoea (54%), hypertension (54%), and decreased appetite (47%). Baseline serum analyses identified potential new prognostic (interleukin-6, E-selectin, interleukin-8, angiopoietin-2, migration inhibitory factor, and c-MET) or predictive (E-selectin and stromal-derived factor-1) factors for survival. CONCLUSIONS Axitinib/BSC did not improve OS over placebo/BSC in the overall population or in stratification subgroups. However, axitinib/BSC resulted in significantly longer PFS and TTP and higher CBR, with acceptable toxicity in patients with advanced HCC. TRIAL REGISTRATION ClinicalTrials.gov, NCT01210495.
Collapse
|
98
|
Nakatsumi H, Yuki S, Kawamoto Y, Muranaka T, Hatanaka K, Kato T, Meguro T, Nakamura M, Iwanaga I, Uebayashi M, Tateyama M, Eto K, Kudo M, Kato S, Okuda H, Sogabe S, Miyashita K, Sakata Y, Sakamoto N, Komatsu Y. 2092 Updated analysis: Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin(OX)+BV and oral FU/OX+BV. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31014-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
99
|
Kobayashi Y, Yuki S, Kawamoto Y, Sawada K, Miyagishima T, Ehira N, Iwanaga I, Okuda H, Tateyama M, Tsuji Y, Hatanaka K, Nakamura M, Kudo M, Fukushima H, Tagaki T, Hisai H, Koike M, Abe R, Sakata Y, Komatsu Y. 2094 Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS Exon2 wild-type metastatic colorectal cancer: HGCSG1001 (Japanese Skin Toxicity Evaluation Protocol With Panitumumab: J-STEPP): Updated analysis of anti-tumor efficacy. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31016-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
100
|
Nakamura M, Yuki S, Nakatsumi H, Muto O, Hosokawa A, Kato T, Iwanaga I, Hatanaka K, Tsuji Y, Sato A, Eto K, Furukawa K, Okuda H, Onodera M, Fujikawa K, Kudo M, Yokoyama S, Honda T, Sakata Y, Komatsu Y. 2096 Phase II trial of Irinotecan plus S-1 (IRIS) with Cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type of metastatic colorectal cancer (mCRC): HGCSG0902 updated analysis. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31018-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|